Dashboard
Manage Tickers

MKKGY MERCK Kommanditgesellschaft...


$ 0.67 (2.6 %)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 611.99 $ 7.61 (1.26 %)
DIA $ 467.41 $ 5.24 (1.13 %)
SPY $ 671.81 $ 6.91 (1.04 %)
TLT $ 91.66 $ 0.35 (0.38 %)
GLD $ 401.83 $ 14.16 (3.64 %)
$ 26.45
-- x --
-- x --
-- - --
$ 23.88 - $ 35.31
114,269
na
nm
$ 0.84
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

fda-unveils-first-experimental-drugs-under-fast-track-voucher-plan-to-cut-drug-review-times
FDA Unveils First Experimental Drugs Under...
10/17/2025 14:03:18

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, a...

emd-serono-cvs-health-to-partner-on-trumprx-fertility-program-launching-in-2026
EMD Serono, CVS Health To Partner On Trump...
10/17/2025 13:50:56

Trump and EMD Serono strike a deal to cut fertility drug costs, expand U.S. manufacturing, and launch the TrumpRx Fertility pro...

avantor-stock-jumps-as-activist-investor-urges-sale-board-shake-up-and-cost-cuts
Avantor Stock Jumps As Activist Investor U...
08/11/2025 15:57:22

Engine Capital, holding a 3% stake in Avantor, urges the board to pursue a turnaround or sale, citing years of underperformance...

Core News & Articles
SpringWorks Therapeutics To Be Acquired by...
04/28/2025 06:35:26

Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3....

weride-crispr-and-genedx-are-among-top-10-mid-cap-gainers-last-week-feb-10-feb-14-are-the-others-in-your-portfolio
WeRide, CRISPR And GeneDx Are Among Top 10...
02/16/2025 14:45:19

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28....

germanys-merck-in-talks-to-buy-cancer-drug-maker-springworks-therapeutics
Germany's Merck In Talks To Buy Cancer Dru...
02/11/2025 16:41:46

Merck KGaA is in advanced talks to acquire SpringWorks, whose portfolio could bolster Merck's oncology business amid patent...

gsk-to-buy-us-based-stomach-cancer-drug-developer-for-over-1-billion
GSK To Buy US-Based Stomach Cancer Drug De...
01/13/2025 15:34:49

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in earl...

Core News & Articles
C4 Therapeutics Has Entered Into A License...
03/04/2024 12:05:55

pfizer-clears-required-regulatory-hurdles-to-complete-43b-seagen-acquisition
Pfizer Clears Required Regulatory Hurdles ...
12/12/2023 18:03:58

Pfizer Inc (NYSE: PFE) 

merck-germanys-two-pivotal-trials-flunk-in-multiple-sclerosis
Merck Germany's Two Pivotal Trials Flunk I...
12/06/2023 13:48:04

Merck KGaA (OTC: MKGAF) (OTC: 

life-sciences-player-repligens-strategic-european-acquisition---what-it-means-for-investors
Life Sciences Player Repligen's Strategic ...
09/26/2023 19:07:02

Repligen Corporation (NASDAQ: RGEN) agreed to acquire Sweden-based privately-held Metenova. 

Core News & Articles
Exscientia And Merck Collaborate On AI-Dri...
09/20/2023 07:24:48

merck-germany-reports-5-decline-in-q2-sales-expects-more-decline-in-2023
Merck Germany Reports 5% Decline In Q2 Sal...
08/03/2023 15:27:41

Merck KGa Germany (OTC: MKGAF) (OTC: MKKGY) reported 

novo-nordisks-obesity-drug-saxenda-not-included-in-whos-essential-drug-list
Novo Nordisk's Obesity Drug Saxenda Not In...
07/26/2023 14:24:05

The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen

abcam-downgrade-analyst-trims-expectations-amid-activist-investor-engagement-and-potential-bid-anticipation
Abcam Downgrade: Analyst Trims Expectation...
06/20/2023 18:37:22

RBC Capital Markets has downgraded Abcam PLC (NASDAQ: ABCM) from Outperform to Sector Perform with a price target of $22, 

analyst-says-nektar-therapeutics-rezpeg-prioritization-likely-to-spark-investor-questions
Analyst Says Nektar Therapeutics' Rezpeg P...
04/18/2023 11:20:40

fda-issues-partial-clinical-hold-on-merck-germanys-multiple-sclerosis-study
FDA Issues Partial Clinical Hold On Merck ...
04/12/2023 14:12:43

merck-germany-regains-exclusive-global-rights-to-cancer-drug-from-pfizer
Merck Germany Regains Exclusive Global Rig...
03/27/2023 17:23:19

incyte-would-now-compete-with-merck-pfizer-as-its-skin-cancer-treatment-scores-fda-accelerated-approval
Incyte Would Now Compete With Merck, Pfize...
03/23/2023 11:39:19

with-upcoming-ovarian-cancer-data-analyst-sees-100-upside-for-mersana-therapeutics
With Upcoming Ovarian Cancer Data, Analyst...
01/20/2023 20:16:38

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION